Road traffic injuries and alcohol use in the emergency department in Tanzania: a case-crossover study
Abstract
Abstract
Introduction: Alcohol is the leading risk factor for road traffic injury (RTI). Africa has the second-highest rate of alcohol dependence and the highest road traffic fatality rate. We describe the proportion of Tanzanian emergency department (ED) patients presenting with RTIs who are blood alcohol content (BAC) positive and determine the dose-response relationship between drinking and injury risk.Methods: Analysis of data from EDs in Tanzania from 2013 to 2014 was performed. Adults presenting to an ED within 6 hours of injury had BAC testing and were asked whether and how much alcohol was consumed prior to the injury. Data also included self-reported alcohol use during control periods 1 day and 1 week prior to the injury. Case-crossover analysis of injury risk used logistic regression to determine matched-pair odds ratios (ORs) and 95% confidence intervals (CIs).Results: Of 513 injury patients, 375 (73%) suffered RTIs. Overall, 29% of RTI patients were BAC-positive. Approximately 40% of those who reported using alcohol prior to RTI reported drinking more than 5 standard drinks. With any alcohol, drivers of both motorcycles and cars/trucks had increased odds of RTI (4.90 OR (CI 2.5-9.5) and 5.70 OR (CI 2.8-11.6) respectively). While the odds of RTI in car/truck drivers demonstrated a dose-dependent response, that in motorcyclists was highest after 3-4 drinks (5.60 OR, CI 2.22-14.10).Discussion: The RTI burden in Tanzania is high. Any alcohol can increase RTI risk.…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.